A peptide supply agreement in Australia is a contract that fixes what a supplier will deliver, to what specification, at what volume and price, and under which regulatory obligations. For a research laboratory, the clauses that carry the most weight are the specification and certificate of analysis (COA) terms, batch documentation, change notification, and a clear statement of the regulatory status of the goods under the Therapeutic Goods Act 1989. This article sets out how such agreements are structured, which clauses to negotiate, and how to test a supplier before signing.
What a peptide supply agreement covers
A supply agreement is the commercial and legal backbone of a recurring purchasing relationship. It converts an informal sequence of orders into a defined arrangement with predictable obligations on both sides. In peptide procurement the document typically addresses six areas:
- Product and specification: the peptide, its sequence or identifier, form (lyophilised powder, for example), vial size, and the purity specification against which each batch is released.
- Quantity and forecasting: committed or indicative volumes, minimum order quantities, and lead times.
- Price and payment: unit or tiered pricing, currency, payment terms, and any shipping fee structure.
- Delivery and risk: dispatch point, carrier, cold-chain or temperature requirements, and the moment risk transfers to the purchaser.
- Quality and documentation: COAs, batch records, retention samples, and the process for rejecting non-conforming material.
- Regulatory and liability terms: compliance warranties, recall cooperation, indemnities, confidentiality and termination.
A single purchase order may suffice for a one-off vial. A written agreement becomes valuable when a project depends on the same material across months, because it keeps the supplied lot, its analytical profile and its documentation consistent through the whole study.
Supply Agreement versus Quality Agreement
In pharmaceutical and research peptide supply, the Quality Agreement is a separate, legally binding document that sits beside the Supply Agreement. The Supply Agreement handles business, financial and legal terms. The Quality Agreement allocates technical responsibilities: GMP compliance, change management, stability testing protocols and release specifications. A published Australian quality and GMP service agreement template illustrates how such technical obligations are drafted as their own instrument.
The practical consequence concerns conflicts. Where the two documents disagree, practitioners generally give precedence to the Supply Agreement on business and legal questions and to the Quality Agreement on technical quality questions. An agreement should therefore state this hierarchy expressly rather than leave it to inference.
Smaller laboratories rarely negotiate a standalone Quality Agreement. In that case, a quality schedule annexed to the supply agreement achieves the same end, provided it names the specification, the test methods, the COA format and the notification duties.
The regulatory baseline: why "research use only" is not a contractual shield
Before any clause is drafted, both parties need an accurate view of the regulatory position, because no contract can lawfully supply what the law does not permit.
Under the TGA's guidance, peptide products classified as therapeutic goods must be entered in the Australian Register of Therapeutic Goods (ARTG) before they can be lawfully imported, manufactured or supplied, unless an exemption, approval or authority applies. Unregistered peptide products are treated as unapproved therapeutic goods that have not been assessed for safety, quality or effectiveness. The same TGA page states that a "research use only" or "not for human use" disclaimer does not alter the regulatory status of a product or permit supply of unapproved goods.
The TGA's Chief Medical Advisor, Professor Robyn Langham, has addressed the same misconception: the central hazard in unapproved peptide markets is the inability to verify contents, sterility or concentration, with products frequently poorly labelled or identified only by codes.
Three implications follow for contract drafting:
- Do not rely on a label. A clause that merely recites "for research use only" provides no protection to either party. The agreement should instead describe the actual end use, the purchaser's institutional setting, and any approval, permit or authority the purchaser holds.
- Allocate regulatory responsibility explicitly. Each party should warrant that it holds, or will obtain, every permit and authority required for its part of the chain, and should be obliged to notify the other of any change.
- Seek advice on status. Whether a given peptide is a therapeutic good, a scheduled substance or neither depends on the compound and its intended use. Confirm the position with the TGA or a lawyer experienced in therapeutic goods law before committing to volumes.
Enforcement is not theoretical. In 2026 the ABF and TGA, with Victoria Police, charged three people after a seizure of steroids and peptides valued at over $2 million. Importing prohibited goods without a permit can attract significant fines and imprisonment under the Customs Act 1901. For the practical customs side, see our analysis of peptide seizures and customs risks in Australia and the overview of import permits for Australian researchers.
Clauses that matter most
The following table summarises the clauses that most often determine whether a peptide supply agreement works in practice.
| Clause | What to specify | Why it matters |
|---|---|---|
| Specification | Identity method, minimum purity (for example by HPLC), appearance, net peptide content, residual solvents where relevant | Defines the pass/fail standard for every batch |
| COA terms | Issued per batch, by an independent laboratory, with batch number matching the vial label | Allows verification rather than trust |
| Batch records | Retention of auditable batch records for an agreed period | Primary evidence in any regulatory audit |
| Change control | Written notice before any change to synthesis route, site, excipients or packaging | Prevents silent shifts that invalidate comparative data |
| Stability and storage | Storage conditions, shelf life, transport temperature | Protects material integrity between release and use |
| Rejection and remedy | Inspection window, replacement or refund process, testing arbitration | Avoids disputes over contested lots |
| Adverse event reporting | Duty to notify of safety events or contamination findings | Required where goods may reach clinical settings |
| Regulatory compliance | Warranties on permits, ARTG status or exemption, and cooperation with the TGA | Allocates legal risk transparently |
| Termination and continuity | Notice periods, last-time buy rights, tech transfer where relevant | Protects multi-month studies |
Specification and COA
A purity figure means little without the method and the laboratory behind it. The agreement should name the analytical method, define how the percentage is calculated, and require that the COA be generated by an independent third-party laboratory and tied to a unique batch number. It should also set out what happens when a retained sample fails retesting: replacement at the supplier's cost, and notification of any other purchasers of the same lot where appropriate.
Our guide to spotting counterfeit peptides in Australia describes five verification checks a laboratory can run against these documents, and the explainer on what "pharmaceutical grade" means in Australia clarifies why that term should always be backed by a defined specification.
Batch size, GMP and documentation
Practitioners emphasise that GMP compliance is a regulatory requirement enforced through standards such as ICH Q7, not a voluntary option, where goods enter the regulated pharmaceutical chain. Contracts in that setting should define batch size, stability protocols and reporting obligations for adverse drug events, and the supplier must maintain auditable batch records. For laboratories working strictly in vitro, full GMP may not apply, but the same documentary discipline remains the best protection for data integrity.
Change control
A peptide synthesised by a different route or at a different site may carry a different impurity profile even at the same headline purity. A change-notification clause, giving the purchaser advance written notice and the right to qualify the new material, is inexpensive to include and difficult to add after a dispute.
Quantities, minimums and forecasting
Many suppliers set minimum order quantities that suit manufacturers rather than academic groups. Agreements for smaller laboratories commonly use indicative forecasts, call-off orders and tiered pricing instead of fixed commitments. Tactics for working under large thresholds are covered in our article on moving below a 100 g peptide MOQ.
Delivery, dispatch and risk transfer
The agreement should record the dispatch location, the carrier and the point at which risk passes. Domestic dispatch removes the customs step from the delivery chain, which narrows the window for delay and for seizure of in-transit goods. Where temperature control matters, state the acceptable transport conditions and who bears the cost of a temperature excursion. Further detail is in our overview of peptide shipping in Australia.
GLP-1 receptor agonists: a distinct regime
Agreements involving GLP-1 receptor agonists require particular caution. Following changes effective 1 October 2024, GLP-1 receptor agonists were removed from the general pharmacy compounding exemption. Pharmacists and medical practitioners must now meet specific criteria under Schedule 8 of the Therapeutic Goods Regulations 1990 to be exempt from holding a manufacturing licence for these products.
The Minister for Health has described the change as a response to commercial-scale replica weight-loss products that bypass standard safety requirements. Quality concerns are not confined to Australia: the FDA's GLP-1 import alert shows how supply-chain quality for these compounds is under scrutiny internationally, which is a further reason to demand supplier-level documentation.
For a supply agreement, the lesson is to state the permitted use of any GLP-1 material precisely, to require the purchaser to confirm its authority in writing, and to avoid any wording suggesting suitability for human or veterinary administration.
Testing a supplier before signing
A contract is only as reliable as the counterparty. A structured due-diligence sequence reduces the risk of committing to an unreliable source:
- Request three recent COAs for different batches and confirm that batch numbers, methods and laboratory identity are consistent and independently verifiable.
- Order a trial quantity and send a retained portion to an independent analytical laboratory for confirmation of identity and purity.
- Confirm the dispatch origin and the carrier, and ask for realistic lead times in writing.
- Ask how regulatory status is handled, including which permits or authorities the supplier holds and how it treats purchasers' obligations.
- Review the change-control and recall process before price is negotiated, not afterwards.
- Check for personal-import workarounds. The TGA notes that so-called personal import schemes are frequently used to disguise commercial-scale supply; a supplier proposing one should be treated with caution.
Further criteria are set out in our guide to local peptide sourcing in Australia and the shortlist and checklist for peptide manufacturers.
Perspective: how we approach supply relationships
We regard documentation as the product's second component. A vial without a verifiable batch record cannot support reproducible research, whatever its nominal purity. For that reason our positioning rests on independent third-party testing to a purity above 99% and a COA for every batch, which the purchaser can check against the batch on the label.
We also hold that a supplier should not rely on a label to define its obligations. Our products are sold for laboratory research, and we advise every purchaser to confirm its own regulatory position and permissions before ordering, particularly for compound classes under active TGA attention. Dispatch from Melbourne within one business day, with discreet packaging, removes customs from the delivery chain and gives purchasers a predictable domestic timeline. Agreements built on those facts, a specified product, a documented batch and a defined delivery, are the ones that hold up.
— Dr. Authur
Ordering from Au Peptide Labs
Laboratories that want to qualify a supplier before committing to a longer arrangement can start with a catalogue order. Au Peptide Labs stocks research peptides across metabolic and GLP-1, recovery and repair, growth hormone secretagogue, cognitive and sleep, and longevity categories, together with laboratory supplies. Express Post is available for a one-off fee of $10. Custom and bulk procurement can be arranged on request through the Au Peptide Labs store. All products are for laboratory research only, not for human or veterinary use.
Frequently asked questions
Does a "research use only" label make a peptide supply agreement lawful?
No. The TGA states that such disclaimers do not change the regulatory status of a product or permit supply of unapproved goods. The lawfulness of a supply depends on the goods' status under the Therapeutic Goods Act 1989 and on any permit, exemption or authority the parties hold. Seek advice from the TGA or a therapeutic goods lawyer where status is uncertain.
What is the difference between a supply agreement and a quality agreement?
The supply agreement covers commercial, financial and legal terms. The quality agreement allocates technical duties such as GMP compliance, change management, stability testing and release specifications. Where they conflict, the supply agreement usually governs business and legal matters and the quality agreement governs technical quality matters.
Which clauses should a small laboratory prioritise?
Prioritise the purity specification with its test method, per-batch independent COAs, change notification, a rejection and replacement process, and clear regulatory warranties. Minimum order quantities and forecasting terms come next, since they determine cost and flexibility.
Are GLP-1 peptides treated differently?
Yes. Since 1 October 2024 GLP-1 receptor agonists have been outside the general pharmacy compounding exemption, and practitioners must meet Schedule 8 criteria under the Therapeutic Goods Regulations 1990. Agreements involving these compounds should state the permitted use precisely and record the purchaser's authority.
Sources
- TGA: How we regulate therapeutic peptide products
- TGA: Understanding your responsibilities when importing, compounding and supplying unapproved peptide products
- TGA: Peptide products
- ABF: Three Victorians arrested following seizure of steroids and peptides
- Department of Health: Protecting Australians from unsafe compounding of replica weight-loss products
- Steritech: Quality GMP service agreement template